Accurate and standardized measurements are essential. Even small differences in technique can lead to large variations in results, so please follow the instructions carefully.

What You Need

• A soft, flexible measuring tape (tailor’s tape)
• A mirror (optional but helpful)
• Light, fitted clothing or minimal clothing
• A relaxed standing posture

Required Measurements

Participants should provide:

• Height
• Weight
• Neck circumference
• Chest circumference
• Waist circumference
• Hip circumference

Each measurement should be taken twice, and the average recorded.

1. Height

How to measure:

• Stand barefoot on a flat surface (no shoes)
• Stand straight with heels together
• Keep head level (looking forward, not up or down)
• Measure from the floor to the top of the head

Tips:

• Stand against a wall for accuracy
• Ensure heels, back, and head are aligned if possible

2. Weight

How to measure:

• Use a digital scale on a hard, flat surface (not carpet)
• Weigh yourself without shoes
• Preferably measure in the morning before eating

Tips:

• Avoid holding objects while weighing
• Try to measure at a consistent time of day

3. Neck Circumference

Why it matters:

Neck circumference helps estimate upper-body fat distribution and is a useful indicator in overall body composition profiling.

How to measure:

• Stand upright with shoulders relaxed
• Place the tape just below the Adam’s apple (or midpoint of the neck)
• Wrap the tape around the neck horizontally
• Ensure it is snug but not compressing the skin

Key tips:

• Do not tilt your head up or down
• Keep shoulders relaxed, not raised

4. Chest Circumference

Why it matters:

Chest measurement reflects upper torso size and helps assess muscle and fat distribution in the upper body.

How to measure:

• Wrap the tape around the fullest part of the chest
• Typically, across the nipple line
• Arms should be relaxed at your sides
• Stand naturally without expanding or holding breath

Key tips:

• Do not puff out your chest
• Keep the tape level all the way around

5. Waist Circumference

Why it matters:

Waist circumference is one of the strongest indicators of central fat distribution and metabolic risk.

How to measure:

• Locate the narrowest part of your torso (or midway between ribs and hips if unclear)
• Wrap the tape around your waist horizontally
• Keep it snug but not tight

Key tips:

• Do not suck in your stomach
• Stand relaxed and breathe normally
• Ensure the tape is level all the way around

6. Hip Circumference

Why it matters:

Hip measurement reflects lower-body fat and muscle distribution and is important for body shape and ratio analysis.

How to measure:

• Stand with feet together
• Wrap the tape around the widest part of your hips and buttocks
• Ensure the tape is level and straight

Key tips:

• Do not tilt your hips forward or backward
• Check in a mirror if possible to ensure even placement

Important General Guidelines

To ensure the highest quality data:

• Take all measurements standing in a relaxed posture
• Use the same tape for all measurements
• Measure directly against the body (not over thick clothing)
• Keep the tape level and parallel to the floor
• Avoid pulling the tape too tight or leaving it too loose
• If unsure, repeat the measurement and record the average

Data Consistency Matters

These measurements are used to track changes over time and across individuals. Small differences in technique can significantly affect interpretation, so consistency is more important than precision.

We recommend that participants:

• Measure themselves at the same time of day when possible
• Use the same method each time
• Follow the same sequence of measurements

Summary

Our protocol combines six key body measurements (neck, chest, waist, hip, height, and weight) to create a reliable, standardized dataset when 3D scanning is not available. Together, these measurements provide a strong foundation for analyzing body composition patterns and tracking changes over time.

References:

https://elht.nhs.uk/services/dietetics/body-measuring-techniques

https://www.measurement-toolkit.org/anthropometry/objective-methods/simple-measures-circumference

https://renpho.com/blogs/wellness-fitness-blog/heres-all-you-need-to-know-about-body-tape-measurements?srsltid=AfmBOopMMp2zu8yBn26uhVlPGlQHLkdhnw6ZI829c2cAwhTT6_agDqpw

• Evidence-based guidance on contraindications for GLP-1 receptor agonists (e.g. semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 receptor agonist tirzepatide, and when to review treatment
• A clear list of urgent symptoms that warrant immediate medical attention
• Contraindications that are generally treatment-limiting (absolute) versus those requiring case-by-case medical evaluation (relative)
• Pregnancy, contraception, and breastfeeding considerations, including medication-specific washout periods
• Risks related to pancreatitis, gallbladder, kidney, and gastrointestinal conditions
• Thyroid and genetic safety warnings (MTC, MEN2)
• Allergy and hypersensitivity risks
• Key medication interaction considerations, including absorption-related contraceptive interactions
• Peri-procedure and anaesthesia considerations
• Guidance on safe use and speaking with a prescribing physician

A Note on Terminology

In this article we refer to “GLP-1 and GLP-1/GIP medications” to reflect the fact that the most commonly prescribed agents in this group have different mechanisms. Semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity) act on the GLP-1 receptor only. Tirzepatide (Mounjaro, Zepbound) acts on both the GLP-1 and the GIP (glucose-dependent insulinotropic polypeptide) receptors. Where a recommendation is specific to one medication or to a subset of this class, we note that explicitly.

Our Commitment to User Safety

At SiPhox, we understand that GLP-1 and GLP-1/GIP medications can play an important role in supporting weight management and metabolic health goals. At the same time, user safety must always come first.

We believe it is important for individuals using these medications to fully understand potential contraindications, risks, and warning signs associated with treatment.

Evidence-Based Guidance on Contraindications and Treatment Discontinuation

Below is a summary of contraindications and safety considerations for GLP-1 receptor agonists and tirzepatide as described in current clinical literature and prescribing guidelines.

These recommendations are based on published medical evidence and are intended to help users better understand situations in which treatment may not be appropriate or may require closer medical supervision.

While this information can support awareness and informed decision-making, it is not a substitute for individualised medical evaluation. If a user believes any of these contraindications may apply to them, or is considering stopping their medication for any reason, they should first speak with their prescribing physician.

A licensed clinician is best positioned to interpret these guidelines in the context of the user’s full medical history and determine whether continuation, adjustment, or discontinuation of therapy is appropriate and safe.

When to Seek Urgent Medical Attention

Most side effects of GLP-1 and GLP-1/GIP medications are mild and resolve as the body adjusts. However, certain symptoms can indicate serious complications and should be treated as medical emergencies. Users should seek immediate medical assessment — typically through emergency services or the nearest emergency department — if they experience any of the following:

Possible pancreatitis

• Severe, persistent abdominal pain, particularly in the upper abdomen
• Pain radiating to the back
• Severe or persistent nausea or vomiting, especially when combined with abdominal pain
• Abdominal pain accompanied by fever or marked abdominal tenderness

Severe allergic or hypersensitivity reaction

• Swelling of the face, lips, tongue, or throat
• Difficulty breathing, wheezing, or tightness in the throat
• Widespread rash, hives, or severe itching
• Dizziness, fainting, or rapid heartbeat following injection

Severe gastrointestinal symptoms or dehydration

• Persistent vomiting or inability to keep fluids down for more than 24 hours
• Signs of dehydration: marked thirst, dark urine, very reduced urine output, dizziness on standing, confusion, or rapid heartbeat
• Severe diarrhoea, particularly if combined with vomiting

Possible gallbladder complications

• Sudden, severe upper-right or central abdominal pain, especially after meals
• Pain radiating to the right shoulder or back
• Fever combined with abdominal pain
• Yellowing of the skin or eyes (jaundice)
• Pale stools or dark urine

Possible kidney injury

• A significant drop in urine output
• New or worsening swelling in the legs or ankles
• Confusion or marked fatigue, particularly in the context of vomiting or diarrhoea

If a user is unsure whether their symptoms are serious, the safest course is to seek medical assessment rather than wait. Users should not stop their medication on their own without first speaking with their prescribing physician unless instructed to do so in an emergency setting.

Contraindications:

Situations in which taking GLP medications is strongly discouraged, or where the medication should be stopped immediately if already in use.

This recommendation is based on the potential for clinically significant health risks that should be reviewed with your Primary Care Physician (PCP) prior to initiating or continuing this medication. If you have any concerns or develop new symptoms, please consult your PCP before making changes to your treatment plan. The following contraindications and precautions may include, but are not limited to, the conditions listed below:

1. Personal or Family History of Medullary Thyroid Carcinoma (MTC)

Most medications in this class — including semaglutide, liraglutide, dulaglutide, exenatide extended-release, and tirzepatide — carry a U.S. boxed warning relating to the potential risk of thyroid C-cell tumours. This warning is based on preclinical animal studies in which sustained exposure to certain GLP-1 receptor agonists was associated with the development of these tumours. While the direct risk in humans has not been definitively established, this precaution is well recognised in medical literature, prescribing information, and clinical guidelines.

Because of this established safety concern, these medications are generally considered contraindicated in users with:

• A personal history of MTC
• A family history of MTC

Healthcare providers are advised to carefully review a patient’s personal and family medical history before initiating treatment. Users should also promptly report symptoms that could suggest thyroid-related complications, including:

• A lump or swelling in the neck
• Persistent hoarseness
• Difficulty swallowing
• Shortness of breath

2. Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)

MEN2 is a hereditary endocrine disorder associated with a significantly increased risk of developing medullary thyroid carcinoma and other endocrine tumours. Because individuals with MEN2 already carry an elevated baseline risk for thyroid C-cell abnormalities, GLP-1 and GLP-1/GIP medications are generally considered contraindicated in this population.

This precaution is widely recognised in clinical practice and is included in FDA labelling and prescribing guidance for several medications in this class. Before prescribing treatment, healthcare providers typically assess for any known personal or family history of MEN2 or related endocrine cancers.

Users with MEN2 or suspected MEN2 should discuss all treatment options carefully with their endocrinologist or prescribing physician. In many cases, alternative therapies may be considered more appropriate depending on the patient’s overall medical history and risk profile.

3. History of Severe Hypersensitivity

A prior severe allergic or hypersensitivity reaction to a specific GLP-1 or GLP-1/GIP medication represents a strict contraindication to continued use of that medication and, in some cases, related medications within the same class. Although severe reactions are uncommon, they are well documented in medical literature and post-marketing safety reports.

Serious hypersensitivity reactions may include:

• Facial or throat swelling (angioedema)
• Difficulty breathing
• Severe rash or hives
• Anaphylaxis

Because allergic reactions can rapidly become life-threatening, users experiencing symptoms suggestive of a severe reaction should seek immediate medical attention (see urgent warning section above). Healthcare providers should also review any previous medication allergies or reactions before initiating therapy.

Even if symptoms appear mild initially, recurrent exposure after a significant hypersensitivity reaction may increase the risk of a more severe response in the future. For this reason, careful medical evaluation is essential before restarting or switching medications within this class after any suspected allergic event.

4. Pregnancy, Pregnancy Planning and Contraceptive Health

GLP-1 and GLP-1/GIP medications are not recommended during pregnancy. Human safety data are limited and animal studies of several agents in this class have demonstrated adverse fetal outcomes, including reduced fetal growth and developmental abnormalities at clinically relevant exposures. Intentional weight loss is also not recommended during pregnancy because it offers no benefit to a pregnant patient and may cause fetal harm.

A defining feature of these medications is their extended duration of action, which is why preconception planning is especially important. Recommended washout periods vary by medication because half-lives differ substantially:

• Semaglutide (Ozempic, Wegovy, Rybelsus) — half-life approximately 1 week. The FDA label recommends discontinuation at least 2 months before a planned pregnancy.
• Tirzepatide (Mounjaro, Zepbound) — half-life approximately 5 days. The FDA label recommends discontinuation at least 1 month before a planned pregnancy; some reproductive medicine literature suggests 25–35 days is a reasonable minimum, with longer intervals where feasible.
• Liraglutide (Victoza, Saxenda) — half-life approximately 13 hours. Discontinuation at least 3 days before conception is generally considered sufficient based on its pharmacokinetics.
• Dulaglutide (Trulicity) — long half-life of approximately 5 days; discontinuation roughly 1 month before conception is often recommended.

If a user becomes pregnant while taking any of these medications, the medication should be discontinued and the prescribing physician contacted promptly. The presence of the drug in early pregnancy is not, in itself, considered an indication for pregnancy termination, but it should be reviewed with an obstetric clinician. Several manufacturers maintain pregnancy exposure registries that users and their providers may wish to contact.

Recommendations:

• Users planning pregnancy should discuss the timing of medication discontinuation with their healthcare provider well in advance of trying to conceive
• Users who become pregnant while taking any medication in this class should notify their prescribing physician as soon as possible
• Alternative diabetes or metabolic management strategies may be recommended during pregnancy depending on the individual’s clinical needs

Contraception (Important for Tirzepatide)

Because GLP-1 and GLP-1/GIP medications slow gastric emptying, the absorption of orally administered drugs — including oral contraceptive pills — may be reduced, particularly early in treatment and after each dose increase.

This is most explicitly addressed in the FDA labels for tirzepatide (Mounjaro and Zepbound), which advise that users of oral hormonal contraceptives:

• Switch to a non-oral contraceptive method (e.g. intrauterine device, contraceptive implant, injection, patch, or vaginal ring), or
• Add a barrier method of contraception (e.g. condoms)
• For 4 weeks after initiating tirzepatide and for 4 weeks after each dose escalation

Non-oral hormonal methods are not expected to be affected by tirzepatide and do not require backup contraception based on this mechanism.

For other medications in this class (e.g. semaglutide, liraglutide), the prescribing labels do not contain an equivalent specific recommendation. However, because the underlying mechanism — delayed gastric emptying — is shared across the class to varying degrees, some clinicians take a similar precautionary approach during dose initiation and escalation, particularly for users in whom an unplanned pregnancy would be a significant concern. Users should discuss contraception planning with their prescribing physician.

Moderate / Relative Contraindications

The following conditions are considered moderate or relative contraindications. Treatment may still be appropriate in certain cases, but additional medical evaluation, monitoring, and risk-benefit assessment are often necessary.

Clinical decisions should always be individualised based on the user’s medical history, current health status, laboratory findings, and guidance from their prescribing physician.

1. Breastfeeding

There are currently insufficient human data to determine whether GLP-1 or GLP-1/GIP medications are excreted into breast milk or how they may affect a nursing infant. The FDA labels for both tirzepatide and semaglutide note that data are absent or limited in this area. Because of the limited evidence, caution is generally advised during breastfeeding.

Healthcare providers must weigh the potential benefits of treatment for the mother against any theoretical risks to the infant. In some situations, alternative therapies with more established safety data during lactation may be preferred.

Additional factors that may influence decision-making include:

• The age and health status of the infant
• The mother’s metabolic or diabetes-related health needs
• The severity of obesity-related medical conditions
• Whether the medication is being used primarily for weight management or glycaemic control

Recommendations:

• Users should discuss breastfeeding plans with their prescribing physician before starting or continuing therapy
• Careful monitoring and individualised medical guidance are recommended if treatment is continued during lactation

2. History of Pancreatitis

Cases of acute pancreatitis have been reported in individuals taking GLP-1 and GLP-1/GIP medications. A definitive causal relationship has not been fully established, and large randomised trials have not consistently shown an increased risk. Nonetheless, because pancreatitis can become severe and potentially life-threatening, caution is advised in users with a prior history of pancreatic disease or other significant risk factors.

Symptoms of pancreatitis may include:

• Severe or persistent abdominal pain
• Pain radiating to the back
• Nausea and vomiting
• Fever or abdominal tenderness

Pancreatitis is uncommon but potentially serious. Users who develop severe, persistent abdominal pain — particularly with nausea or vomiting — should seek urgent medical assessment.

Users with the following risk factors may require closer monitoring:

• Prior pancreatitis
• Gallstones or biliary disease
• Heavy alcohol use
• Elevated triglyceride levels, particularly severe hypertriglyceridaemia (commonly defined as triglyceride levels above 500 mg/dL, and especially above 1,000 mg/dL)
• Certain metabolic or gastrointestinal disorders that may increase pancreatic stress or inflammation risk, including:
  • Poorly controlled type 2 diabetes
  • Obesity associated with metabolic syndrome
  • Active gallbladder disease or gallstones
  • Inherited lipid disorders, such as familial hypertriglyceridaemia

Users with these risk factors may require closer clinical monitoring and individualised evaluation before initiating or continuing therapy.

3. Severe Gastrointestinal Disease (e.g. Gastroparesis)

GLP-1 and GLP-1/GIP medications work in part by slowing gastric emptying, which contributes to appetite reduction and improved blood sugar control. However, this same mechanism may worsen symptoms in users with underlying gastrointestinal motility disorders such as gastroparesis.

In severe cases, delayed gastric emptying can interfere with hydration, nutrition, and the absorption of other oral medications. Because gastrointestinal side effects are among the most common adverse effects associated with this class, users with pre-existing digestive disorders often require careful assessment before treatment initiation.

Healthcare providers may consider:

• Lower starting doses
• Slower dose escalation
• Alternative medications
• Ongoing symptom monitoring

Users experiencing severe or worsening gastrointestinal symptoms — particularly persistent vomiting, inability to keep fluids down, or signs of dehydration — should contact their healthcare provider promptly or seek urgent care (see urgent warning section above).

4. Chronic Kidney Disease

Some GLP-1 and GLP-1/GIP medications may require caution in users with moderate to severe kidney impairment, particularly those at risk for dehydration or acute kidney injury. While several agents in this class can be used safely in certain stages of chronic kidney disease, severe gastrointestinal side effects such as vomiting or diarrhoea may worsen kidney function due to fluid loss and electrolyte imbalance.

Users with advanced kidney disease may be more vulnerable to:

• Dehydration
• Acute kidney injury
• Electrolyte abnormalities
• Reduced medication tolerance

Clinical monitoring may include:

• Kidney function testing
• Hydration assessment
• Monitoring for gastrointestinal adverse effects
• Medication dose review

Because recommendations vary between individual medications, treatment decisions should be based on the specific medication prescribed and the severity of kidney impairment.

5. Gallbladder Disease

GLP-1 and GLP-1/GIP medications have been associated with an increased risk of gallbladder-related complications, including gallstones and inflammation of the gallbladder. Rapid weight loss itself may also increase the likelihood of gallstone formation, which can make it difficult to distinguish medication-related effects from weight-loss-related risk factors.

Potential gallbladder complications may include:

• Gallstones (cholelithiasis)
• Gallbladder inflammation (cholecystitis)
• Biliary colic
• Bile duct obstruction

Symptoms that may require urgent medical evaluation include:

• Upper abdominal pain, especially after eating
• Pain radiating to the shoulder or back
• Fever
• Nausea or vomiting
• Yellowing of the skin or eyes (jaundice)

Users with a prior history of gallbladder disease should discuss these risks with their healthcare provider before starting treatment. In some cases, additional monitoring or alternative therapies may be considered depending on the individual’s medical history and symptom severity.

Surgery, Anesthesia, and Procedural Sedation

Because GLP-1 and GLP-1/GIP medications slow gastric emptying, food and fluid can remain in the stomach for longer than expected. In the context of anaesthesia or procedural sedation, this can theoretically increase the risk of regurgitation and pulmonary aspiration (stomach contents entering the lungs) even after standard fasting periods.

Recommendations in this area have evolved. Earlier 2023 guidance from the American Society of Anesthesiologists suggested holding daily-dose medications on the day of a procedure and weekly-dose medications one week before. Updated multi-society guidance issued in October 2024 — endorsed by the American Society of Anesthesiologists, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons — concluded that most patients can continue their medication before elective surgery, with risk-stratified precautions rather than blanket discontinuation.

The updated approach focuses on:

• Shared decision-making between the user, the prescribing physician, the surgeon, and the anaesthesia team
• Day-of-procedure assessment for symptoms suggestive of delayed gastric emptying (such as nausea, bloating, or recent vomiting)
• A 24-hour clear liquid diet prior to the procedure for users considered at higher risk (e.g. those still in dose escalation, on higher doses, or with persistent gastrointestinal symptoms)
• Anaesthetic plan adjustments where appropriate to minimise aspiration risk
• Point-of-care gastric ultrasound in selected high-risk cases, where available, to assess gastric contents before sedation

Key user guidance:

• Always inform the anaesthesia and surgical team that you are taking a GLP-1 or GLP-1/GIP medication, including the specific drug, dose, and timing of your most recent dose
• Do not stop or hold your medication ahead of a procedure without confirmation from your prescribing physician and the procedural team — abrupt discontinuation may also have implications for glycaemic control
• Follow any procedure-specific fasting or pre-procedure diet instructions provided by your care team
• Mention this medication for any procedure involving sedation, including endoscopy, colonoscopy, dental work under sedation, and elective surgery

Current Medications and Interaction Risk

Before starting GLP-1 or GLP-1/GIP therapy, you should inform your clinician of all medications you are taking, including prescription drugs, over-the-counter treatments, and supplements. This is important because these medications slow gastric emptying and intestinal transit, which can affect how other drugs are absorbed and tolerated.

Special attention should be paid to the following categories:

• Medications with narrow therapeutic windows, where small changes in blood levels can have significant effects
  • Examples: warfarin, levothyroxine, lithium, digoxin
• Medications requiring consistent absorption or timing, where altered absorption may reduce efficacy or stability
  • Examples: levothyroxine, oral contraceptives, tacrolimus, certain antiepileptics
• Oral hormonal contraceptives — see the dedicated contraception section above, particularly for tirzepatide
• Diabetes medications that increase hypoglycaemia risk when combined
  • Examples: insulin, sulfonylureas such as glipizide or gliclazide
• Medications that affect gastrointestinal motility or are affected by it
  • Examples: metoclopramide, loperamide, erythromycin
• Users on complex polypharmacy or unstable regimens — for example, multiple cardiovascular, psychiatric, or endocrine medications with frequent dose adjustments
  • Examples: antidepressants (sertraline, amitriptyline), antiepileptics (valproate, carbamazepine), antihypertensives (amlodipine, beta-blockers such as bisoprolol)

Because therapy can slow digestion, it may alter the timing, absorption, and overall effectiveness of co-administered medications, particularly during dose initiation and escalation. Careful monitoring and individualised dose adjustments may therefore be required under medical supervision.

Key Guidance for Users

Users taking GLP-1 or GLP-1/GIP medications should:

• Be informed of all potential contraindications before starting treatment
• Recognise the urgent warning signs above and know when to seek emergency care
• Report new or worsening symptoms promptly to their physician
• Inform any clinician treating them — including anaesthesia and dental teams — that they are taking the medication
• Maintain regular follow-up with their prescribing healthcare provider
• Never stop or adjust medication without medical guidance, unless instructed to do so as part of an emergency response

Final Note

GLP-1 and GLP-1/GIP medications can offer significant benefits, but they must be used responsibly. Awareness of contraindications, early recognition of warning signs, and clear communication with all members of a user’s care team are essential to safe use.

Users should always consult their prescribing physician to determine whether therapy is appropriate for their specific medical history and to decide when adjustment or discontinuation is necessary.

Disclaimer

This article is intended for general educational purposes only and does not constitute medical advice. It is not a substitute for individualised diagnosis, treatment, or recommendations from a qualified healthcare professional. Clinical guidelines, prescribing information, and the evidence base for these medications continue to evolve; users should rely on their prescribing physician for current, personalised guidance. SiPhox does not assume responsibility for clinical decisions made on the basis of this article. If you believe you are experiencing a medical emergency, contact emergency services or go to the nearest emergency department.

References

1. https://www.ncbi.nlm.nih.gov/books/NBK551568/
2. https://jamanetwork.com/journals/jama/fullarticle/2842199#google_vignette
3. https://link.springer.com/article/10.1007/s12325-022-02394-w
4. https://www.degruyterbrill.com/document/doi/10.7556/jaoa.2011.20020/html
5. https://journals.sagepub.com/doi/abs/10.1177/0145721715607981

The good news: maintaining muscle does not require spending hours in the gym every day. A focused strength routine, done consistently, can go a long way.

Why Muscle Matters More With Age

Maintaining muscle is essential for preserving independence, mobility, and long-term health.

Healthy muscle supports:

• Bone density
• Insulin action
• Balance and coordination
• Daily strength
• Functional independence

Without regular strength training, muscle loss can increase the risk of falls, fractures, frailty, and chronic metabolic issues like type 2 diabetes.

Muscle is not just about strength. It is one of the key systems that helps people stay active, independent, and resilient with age.

Why Strength Fades Faster Than Muscle Size

One of the most important points in aging research is that muscle strength declines faster than muscle mass.

In simple terms, someone may lose strength and function even before major muscle loss is visible. This reflects a decline in “muscle quality,” or how much force the muscle can produce per unit of muscle.

This happens partly because aging affects Type II fast-twitch muscle fibers. These fibers support quick, forceful movements, such as standing up quickly, catching yourself during a stumble, climbing stairs, or changing direction.

For healthy aging, the goal is not just to preserve muscle size. The goal is to preserve muscle function.

Progressive Resistance Training: The Gold Standard

Progressive Resistance Training, or PRT, is the most effective way to counteract sarcopenia.

PRT means training muscles against resistance and gradually increasing the challenge as strength improves. This can be done with machines, free weights, resistance bands, ankle weights, or bodyweight exercises.

Why It Works:

• Builds strength: Helps preserve the force-producing ability of muscle
• Improves muscle quality: Supports better strength per unit of muscle
• Supports daily function: Helps with walking, standing, lifting, and balance
• Trains the nervous system: Helps the brain recruit muscle fibers more effectively
• Can be simple: Does not require expensive equipment

The key is progression. As the body adapts, the resistance needs to increase. If the same routine becomes too easy, the body has less reason to maintain or build strength.

Strength training does not need to be complicated. It needs to be consistent, challenging, and progressive.

The Minimum Effective Workout Schedule

You do not need to spend hours in the gym to see results.

A stronger and more realistic long-term target is two full-body strength sessions per week.

The most minimal version is one focused resistance session per week. Evidence shows that training once per week can be effective for increasing strength in older adults. A single set of exercises performed to muscular fatigue, the point where another repetition cannot be completed with good form, can also be effective for building strength and muscle thickness.

That said, a stronger practical target is 2 strength sessions per week, depending on goals, ability, and consistency.

The Minimum Effective Dose

Best for people who want a realistic starting point for maintaining muscle, strength, and function as they age.

What a Simple Weekly Plan Looks Like

For most people, the easiest structure is 2 full-body strength workouts per week with light movement on the other days.

This gives the body enough stimulus to maintain strength while still allowing time for recovery.

A Simple 12-Week Strength Plan

For a more structured approach, use a 12-week plan with 2 full-body workouts per week.

Each workout includes 5 exercises that cover the upper body, lower body, and hip/core stability. Perform each exercise for 30 seconds, then rest for 1 minute. The goal is to perform the exercise for a continuous 30 seconds rather than reaching a specific number of repetition

This simple progression gives the body a reason to keep adapting without making the plan complicated.

Example Full-Body Workout Mix

Choose 5 exercises per workout. A simple session could look like this:

The goal is not to include every exercise in one session. The goal is to train the major muscle groups over the week in a simple, repeatable way.

Exercise Examples for Upper and Lower Body

A good program includes both multi-joint and single-joint exercises.

Multi-joint exercises train several muscles at once. These include squats, lunges, leg press, chest press, bench press, shoulder press, rows, step-ups, and sit-to-stands.

Single-joint exercises target specific muscles. These include bicep curls, knee extensions, leg curls, calf raises, flys, hip abduction, hip adduction, and hip flexion.

A smart routine includes both. Larger multi-joint exercises usually come first, followed by smaller single-joint exercises. This keeps the most demanding movements earlier in the workout when energy and form are best.

Power Training: The Missing Piece

While PRT builds strength, power training focuses on speed.

Power training means performing the lifting phase of an exercise as quickly and forcefully as possible while staying controlled. This matters because fast-twitch fibers decline with age, and these fibers are important for agility, balance recovery, and fall prevention.

Simple examples include:

• Standing up from a chair quickly
• Rising onto the toes with control
• Performing a quick but controlled row
• Stepping up with intention

Power training should always be safe and appropriate for the person’s ability level.

Strength helps with capacity. Power helps with quick reactions and real-world movement.

Protein, Recovery, and the Sedentary Trap

Exercise gives the muscle a reason to adapt. Nutrition and recovery help the body respond.

With age, muscles can become less responsive to protein and exercise, a process called anabolic resistance. This means adequate protein becomes especially important.

Protein Targets

Recovery also matters. Muscles adapt between workouts, not during the workout itself. Rest days, sleep, and consistent nutrition all support results.

Avoiding long periods of inactivity is also important. Even 14 days of reduced activity can lead to significant muscle loss and a reduced ability to process protein.

Creatine: When combined with resistance training, creatine is a helpful tool for healthy aging. Beyond its role in muscle performance, research has shown promising benefits for lean mass support, recovery, and bone health as well as cognitive function.

Strength training is the signal. Protein, recovery, and regular movement help the body keep responding.

Quick Workout Comparison

What to Look For in a Good Aging-Focused Workout

Workouts should:

• Target upper and lower body
• Include functional movements like sit-to-stand
• Use progressive resistance
• Include rest between sessions
• Be repeated consistently
• Use safe intensity monitoring
• Be adapted to ability level

Try to avoid:

• Only stretching
• Only walking
• No progression over time
• Exercises that feel too easy forever
• Ignoring pain or poor form
• Programs too intense to repeat consistently

Final Recommendation

Skeletal muscle retains a remarkable capacity to adapt, even in individuals over the age of 85.

For most people, the best starting point is simple: perform at least one focused resistance training session per week. For a stronger long-term plan, aim for two full-body strength sessions per week.

The plan does not need to be complicated:

• Train 1 to 2 days per week
• Target 8 to 10 major muscle groups
• Perform at least 1 hard set per exercise
• Aim for 10 to 15 repetitions
• Progress resistance over time
• Include power-focused movements when safe
• Eat enough protein
• Avoid long periods of inactivity

Consistency over time is the greatest ally in maintaining muscle with age. The goal is not perfection. The goal is to keep giving the body a reason to stay strong.

Having trouble determining the best workout routine for you? Get in touch with one of our expert health coaches.

References

1. Di Lorito C, Long A, Byrne A, Harwood RH, Gladman JRF, Schneider S, Logan P, Bosco A, van der Wardt V. Exercise interventions for older adults: a systematic review of meta-analyses. J Sport Health Sci. 2021 Jan;10(1):29-47. doi: [10.1016/j.jshs.2020.06.003](https://doi.org/10.1016/j.jshs.2020.06.003). PMID: [32525097](https://pubmed.ncbi.nlm.nih.gov/32525097/); PMCID: [PMC7858023](https://pmc.ncbi.nlm.nih.gov/articles/PMC7858023/).

2. Izquierdo M, de Souto Barreto P, Arai H, Bischoff-Ferrari HA, Cadore EL, Cesari M, Chen LK, Coen PM, Courneya KS, Duque G, et al. Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR). J Nutr Health Aging. 2025;29:100401. doi: [10.1016/j.jnha.2024.100401](https://doi.org/10.1016/j.jnha.2024.100401). PMID: [39743381](https://pubmed.ncbi.nlm.nih.gov/39743381/); PMCID: [PMC11812118](https://pmc.ncbi.nlm.nih.gov/articles/PMC11812118/).

3. Distefano G, Goodpaster BH. Effects of exercise and aging on skeletal muscle. Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):a029785. doi: [10.1101/cshperspect.a029785](https://doi.org/10.1101/cshperspect.a029785). PMID: [28432116](https://pubmed.ncbi.nlm.nih.gov/28432116/); PMCID: [PMC5830901](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830901/).

4. DiFrancisco-Donoghue J, Werner W, Douris PC. Comparison of once-weekly and twice-weekly strength training in older adults. Br J Sports Med. 2007 Jan;41(1):19-22. doi: [10.1136/bjsm.2006.029330](https://doi.org/10.1136/bjsm.2006.029330). PMID: [17062657](https://pubmed.ncbi.nlm.nih.gov/17062657/); PMCID: [PMC2465144](https://pmc.ncbi.nlm.nih.gov/articles/PMC2465144/).

5. Pereira B, Monteiro D, Matos R, Jacinto M, Amaro N, Antunes R, Rodrigues F. Effect of a 12-week strength training program on muscle strength measures of institutionalized older adults: a pilot study. Healthcare (Basel). 2024 Jul 17;12(14):1428. doi: [10.3390/healthcare12141428](https://doi.org/10.3390/healthcare12141428). PMID: [39057570](https://pubmed.ncbi.nlm.nih.gov/39057570/); PMCID: [PMC11275893](https://pmc.ncbi.nlm.nih.gov/articles/PMC11275893/).

6. Deutz NEP, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, Cederholm T, Cruz-Jentoft A, Krznariç Z, Nair KS, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014 Dec;33(6):929-936. DOI: [10.1016/j.clnu.2014.04.007](https://doi.org/10.1016/j.clnu.2014.04.007). PMID: [24814383](https://pubmed.ncbi.nlm.nih.gov/24814383/); PMCID: [PMC4208946](https://pmc.ncbi.nlm.nih.gov/articles/PMC4208946/).

The post-GLP-1 phase refers to the period during tapering or within the first 6 months after stopping GLP-1 therapy.

During this time, the body transitions away from:

• Appetite suppression
• Slower gastric emptying
• Enhanced insulin sensitivity
• Pharmacologically supported weight regulation

This creates a rebound-prone physiological state, where metabolic and behavioral adaptations may reverse.

Why this phase is high risk

GLP-1 medications actively support appetite control and metabolic regulation. When they are removed:

• Hunger signals increase
• Caloric intake often rises
• Energy expenditure may remain reduced
• Prior metabolic tendencies can re-emerge

Clinical observations show that a significant proportion of lost weight (up to ~40%) may be regained within the first 6 months, alongside deterioration in metabolic markers.

Because of this, the post-GLP-1 phase requires active monitoring, not passive observation.

What biomarkers matter after stopping GLP-1

1. Glycemic and insulin markers

After discontinuation:

• Insulin sensitivity may decrease
• Glucose levels may rise

Tracking helps detect early metabolic regression.

2. Lipid profile

Common trends include:

• Rising triglycerides
• Worsening LDL/HDL balance

These changes may occur gradually but are clinically significant.

3. Weight trajectory (trend-based)

While not a blood biomarker, weight trend is critical:

• Early regain patterns can predict long-term outcomes
• Small increases early often accelerate without intervention

4. Liver function and NAFLD markers

As metabolic health regresses:

• Liver fat may re-accumulate
• ALT / AST may trend upward

5. Hormonal markers (e.g., insulin, testosterone)

Changes in energy balance and body composition may affect:

• Insulin dynamics
• Hormonal regulation

6. Nutritional and protein status

If eating patterns shift toward:

• Higher calorie, lower nutrient intake

There may be a decline in:

• Protein adequacy
• Micronutrient status

What changes are most common after discontinuation

1. Increased appetite and reduced satiety. The most immediate change: hunger signals return and portion sizes increase
2. Weight regain, which is often driven by: increased intake and persistent metabolic adaptation (lower energy expenditure)
3. Worsening glycemic control: particularly in individuals with prior insulin resistance.
4. Lipid rebound: Triglycerides and cholesterol may gradually increase.
5. Behavioral drift: structured eating patterns during therapy may become less consistent.

Why monitoring is critical in this phase

Unlike earlier phases, this stage is not about adaptation to a drug—but adaptation without it.

Without monitoring:

• Early negative trends may go unnoticed
• Weight regain may accelerate
• Metabolic deterioration may become harder to reverse

Biomarkers allow for:

• Early detection of regression
• Timely intervention
• More sustainable long-term outcomes

How to reduce rebound risk

• Maintain structured eating: prioritize protein and meal consistency
• Continue physical activity: especially resistance training to preserve lean mass
• Monitor trends early: small changes are easier to correct than large ones
• Avoid “all-or-nothing” shifts: gradual transition off therapy is preferable to abrupt discontinuation when possible

How often should you monitor

Because this is a high-risk transition period:

• Monthly monitoring for the first ~6 months after stopping GLP-1
• Focus on biomarker trends and weight trajectory
• Continued symptom and behavioral awareness

Key takeaway

The post-GLP-1 phase is a rebound-sensitive period.

A biomarker-driven approach allows for early detection of metabolic drift and supports long-term weight and metabolic stability after therapy ends.

Where can I learn more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

The long-term phase begins after 16 weeks of treatment, once a stable and tolerated GLP-1 dose has been reached.

At this stage:

• Appetite suppression becomes more predictable
• Weight loss slows and stabilizes
• The body reaches a more consistent metabolic state

The focus shifts from short-term adaptation to long-term preservation, optimization, and safety.

How this phase differs from the early phase

While both phases are biomarker-driven, the purpose of monitoring changes:

In this phase, biomarkers are interpreted over time and trends, not in isolation.

Which biomarkers matter most long-term

1. Lipid profile

GLP-1 therapy often improves:

• Triglycerides
• LDL and HDL balance

Monitoring confirms cardiometabolic benefit and trajectory.

2. Glycemic and insulin markers

Long-term improvements in:

• Glucose regulation
• Insulin sensitivity

These markers help assess sustained metabolic health.

3. Liver function and NAFLD markers

GLP-1 therapy is associated with reduced liver fat, making it important to track:

• ALT / AST trends
• Broader liver health markers

4. Hormonal balance

Weight loss and reduced caloric intake can influence:

• Testosterone and Estradiole levels
• Energy, recovery, and body composition

Monitoring ensures hormonal preservation during fat loss.

5. Micronutrient status

Sustained appetite suppression may reduce intake of key nutrients:

• Vitamin B12
• Iron
• Vitamin D

Deficiencies may develop gradually and require proactive monitoring.

6. Protein status and muscle preservation (indirect markers)

Long-term caloric restriction increases risk of:

• Lean mass loss
• Reduced metabolic rate

Biomarkers and clinical context help assess adequacy of:

• Protein intake
• Overall nutritional status

What risks emerge over time

• Muscle loss (sarcopenia): without adequate protein and resistance training, weight loss may include lean mass.
• Micronutrient deficiencies: gradual reductions in intake can lead to deficiencies that are not immediately symptomatic.
• Hormonal suppression: prolonged caloric deficit may affect endocrine balance, particularly testosterone.
• Gallbladder risk is still high. Ongoing weight loss continues to carry risk of: gallstone formation and intermittent biliary symptoms
• Plateaus or suboptimal response. In some individuals: weight loss may plateau or metabolic improvements may stabilize early

Biomarkers help distinguish true plateau vs. modifiable factors.

How to optimize outcomes on GLP-1

• Preserve lean mass: prioritize protein intake and incorporate resistance training
• Maintain nutrient sufficiency: monitor and supplement where needed
• Track trends, not single results: longitudinal data is more clinically meaningfu
• Align lifestyle with treatment: sleep, movement, and diet remain essential for sustained benefit

How often should you monitor

Because this phase is more stable:

• Quarterly (every ~3 months) biomarker testing
• Trend-based interpretation over time
• Continued symptom awareness as supporting context

Key takeaway

The long-term phase of GLP-1 therapy is about optimization and preservation.

It remains biomarker-driven, but shifts focus toward sustaining metabolic improvements, protecting muscle and hormonal health, and preventing slow-developing deficiencies.

Where can I read more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

The early phase (commonly the first ~16 weeks) refers to the period of dose escalation and physiological adaptation to GLP-1 receptor agonists (such as semaglutide, liraglutide, or tirzepatide).

During this phase, the body is adjusting to:

• Slower gastric emptying
• Reduced appetite and caloric intake
• Changes in hydration and electrolyte balance
• Rapid metabolic shifts

This makes it the most dynamic phase of treatment, where both tolerance and early metabolic response need to be monitored closely.

Why monitoring is different in this phase

While both early and later phases rely on biomarkers, the type and purpose of monitoring differ.

In the early phase:

• Biomarkers are used to detect acute physiological stress and tolerance issues
• Changes can occur rapidly and non-linearly
• Symptom context is still important for interpretation

Which biomarkers matter most early on

1. Electrolytes and hydration markers

Reduced food and fluid intake can quickly affect:

• Total Protein
• Kidney function markers (e.g., creatinine trends)

These help detect early dehydration or imbalance.

2. Liver enzymes and metabolic stress

Rapid weight loss and metabolic shifts may transiently affect:

• ALT / AST
• Markers associated with liver fat mobilization

3. Lipid profile (especially triglycerides)

Triglycerides are particularly important early on:

• Elevated levels increase pancreatitis risk
• Rapid metabolic changes may initially destabilize lipid levels

4. Glycemic markers

GLP-1 therapy rapidly affects glucose regulation:

• % HbA1c
• C-Peptide

These help assess early metabolic response and detect excessive drops in intake or imbalance.

5. Nutritional status indicators (early trends)

Even early in treatment, reduced intake may begin to impact:

• Ferritin
• Vitamin D

What symptoms still play a role

Although this is a biomarker-driven phase, symptoms provide essential context for interpreting early changes.

Important symptoms include:

• Persistent nausea or vomiting
• Inability to maintain hydration
• Abdominal pain (especially severe or radiating)
• Dizziness or weakness
• Right upper abdominal discomfort (gallbladder-related)

Symptoms help determine whether biomarker changes reflect:

• Normal adaptation

  or

• Emerging intolerance or risk

Key risks in the early phase

• Gastrointestinal intolerance: driven by delayed gastric emptying and central appetite effects.
• Dehydration and electrolyte imbalance: often due to reduced intake rather than direct drug effect.
• Under-eating and rapid caloric deficit: can begin affecting metabolic stability and lean mass early.
• Gallbladder stress: triggered by rapid weight loss and fat mobilization, rather than routine enzyme screening alone

How to support your body during this phase

• Maintain hydration: fluid intake should be intentional, not appetite-driven.
• Prioritize protein and nutrient density: even small meals should be nutritionally meaningful.
• Monitor both labs and symptoms together: neither should be interpreted in isolation.
• Avoid aggressive dose escalation: tolerance should guide progression.

How often should you monitor

Because this phase is dynamic:

• Monthly biomarker monitoring during the first 16 weeks
• Ongoing symptom tracking for context
• Additional testing if abnormalities or symptoms arise

Key takeaway

The early phase of GLP-1 therapy is about safe adaptation.

It remains biomarker-driven, but focuses on short-term physiological stability, tolerance, and early metabolic shifts, rather than long-term optimization.

Where can I read more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

Pre-GLP-1 baseline testing is a structured health assessment performed before starting GLP-1 receptor agonist medications (such as semaglutide, liraglutide, or tirzepatide).

Its purpose is to establish a true cardiometabolic and clinical reference point before treatment begins, allowing for accurate interpretation of metabolic changes over time.

This includes identifying underlying issues such as:

• Thyroid dysfunction
• Lipid abnormalities
• Testosterone imbalance
• Early fatty liver disease (NAFLD)
• Insulin resistance patterns

Without a baseline, it becomes difficult to distinguish medication effects from pre-existing metabolic or pharmacological influences.

Why a baseline matters before starting GLP-1 therapy

GLP-1 medications can significantly affect:

• Weight and appetite regulation
• Glucose metabolism
• Lipid profiles
• Liver fat content
• Gastrointestinal function and drug absorption

Because these changes can occur rapidly, starting therapy without baseline data reduces interpretability of outcomes.

A structured baseline helps:

• Identify pre-existing metabolic risk
• Detect hidden endocrine or lipid abnormalities
• Establish a clear comparison point for treatment response
• Improve long-term safety and tracking accuracy

What should be assessed before starting GLP-1s?

A comprehensive Pre-GLP-1 baseline focuses on cardiometabolic, endocrine, and pharmacological safety factors:

1. Thyroid function

Thyroid hormones regulate metabolic rate and energy balance. Undiagnosed dysfunction can influence weight response and symptom interpretation.

2. Lipid profile

Elevated triglycerides and dyslipidemia are key metabolic risk factors and relevant for overall cardiometabolic health and pancreatitis risk stratification.

3. Liver health (NAFLD risk)

Non-alcoholic fatty liver disease is closely linked to insulin resistance and may improve significantly with GLP-1 therapy.

4. Sex hormones

Hormonal imbalance can affect fat distribution, energy levels, and metabolic adaptation.

5. Glycemic and insulin markers

These define baseline insulin resistance and expected metabolic response trajectory.

6. Reproductive and pregnancy status

Pregnancy status must be assessed before starting GLP-1 therapy, as these medications are not recommended during pregnancy due to insufficient human safety data and potential fetal risk.

7. Current Medications and Interaction Risk

Before starting GLP-1 receptor agonist therapy, you should inform their clinician of all medications they are taking, including prescription drugs, over-the-counter treatments, and supplements. This is important because GLP-1 medications slow gastric emptying and intestinal transit, which can affect how other drugs are absorbed and tolerated.

Special attention should be paid to the following categories:

• Medications with narrow therapeutic windows (where small changes in blood levels can have significant effects)

Examples: warfarin, levothyroxine, lithium

• Medications requiring consistent absorption or timing (where altered absorption may reduce efficacy or stability)

Examples: levothyroxine, oral contraceptives, tacrolimus

• Diabetes medications that increase hypoglycemia risk when combined

Examples: insulin, sulfonylureas such as glipizide or gliclazide

• Medications that affect gastrointestinal motility or are affected by it

Examples: metoclopramide, loperamide, erythromycin

• Patients on complex polypharmacy or unstable regimens (e.g., multiple cardiovascular, psychiatric, or endocrine medications with frequent dose adjustments)

Examples: antidepressants (sertraline, amitriptyline), antiepileptics (valproate, carbamazepine), antihypertensives (amlodipine, beta-blockers such as bisoprolol)

Because GLP-1 therapy can slow digestion, it may alter the timing, absorption, and overall effectiveness of co-administered medications, particularly during dose initiation and escalation. Careful monitoring and individualized dose adjustments may therefore be required under medical supervision.

When NOT to start GLP-1 medications

GLP-1 therapy should be avoided or delayed in the presence of certain clinical conditions.

You should be made aware of these risks and inform your physician if you have any of the following conditions before starting GLP-1 treatment:

• Active or suspected pancreatitis
• Previous history of pancreatitis
• Unexplained persistent or severe abdominal symptoms
• Untreated or symptomatic gallbladder disease
• Previous history of gallbladder disease
• Severe gastrointestinal disorders affecting gastric emptying
• Uncontrolled endocrine disorders requiring stabilization
• Pregnancy or active attempts to conceive without medical supervision

  GLP-1 receptor agonists are not recommended during pregnancy. Treatment should be avoided or discontinued if pregnancy occurs, with appropriate clinical follow-up.

• History of contraindicated thyroid malignancy (e.g., medullary thyroid carcinoma or MEN2)
• Severe malnutrition or eating disorders requiring primary stabilization
• Unstable or high-risk medication regimens where absorption or dosing cannot yet be safely predicted

In these cases, initiating therapy without addressing underlying risks may reduce safety and clinical clarity.

How baseline and Day 0 testing works

A structured Pre-GLP-1 protocol typically involves two steps:

1. Baseline assessment (pre-screening phase)

• Identifies metabolic, endocrine, reproductive, and medication-related risks
• Establishes eligibility and risk stratification

2. Day 0 (treatment initiation point)

• Re-confirms baseline status immediately before first dose
• Ensures stability of medication and clinical variables
• Locks in reference values for longitudinal tracking

This ensures that all subsequent changes can be attributed to therapy and lifestyle rather than pre-existing variability.

Why this matters clinically

Without structured baseline assessment, GLP-1 response interpretation becomes less precise. For example:

• Weight loss may mask underlying thyroid dysfunction
• Lipid improvements may reflect baseline fluctuation rather than treatment effect
• Gastrointestinal symptoms may be misattributed to medication instead of pre-existing disease or drug interactions
• Medication side effects may be misinterpreted if absorption changes are not accounted for

A structured baseline ensures clarity, safety, and meaningful long-term metabolic insight.

Where can I read more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

Amylase and lipase are digestive enzymes produced by the pancreas.

• Amylase helps break down carbohydrates
• Lipase helps break down fats

In clinical settings, these enzymes are often measured when acute pancreatitis is suspected, as they can rise during active pancreatic inflammation.

However, their role is primarily diagnostic during an acute event, rather than predictive of future risk.

Why we do not rely on amylase and lipase for GLP-1 pancreatitis risk screening?

GLP-1 receptor agonists (such as semaglutide and similar medications) have been associated with pancreatitis. Because of this, monitoring pancreatic safety is important, but enzyme testing alone is not an effective screening tool for risk prediction.

There are several reasons for this:

• They rise acutely after inflammation beginsAmylase and lipase typically increase once pancreatic injury is already underway, not before symptoms develop.
• They are not specific for GLP-1–related riskElevated levels may occur due to gallstones, gastrointestinal conditions, kidney dysfunction, or other non-pancreatic causes.
• They may remain normal in some clinically significant casesParticularly in early, mild, or atypical presentations, enzyme levels can be misleadingly normal.

Because of this, relying solely on these biomarkers may miss early warning signs or overestimate risk in unrelated conditions.

How pancreatitis risk is assessed in GLP-1 users

Instead of routine enzyme testing, pancreatitis risk is better evaluated using a symptom- and risk-factor–based approach, especially in individuals using GLP-1 therapy.

This is why our program includes:

• Structured symptom questionnaires
• Medical and medication history review
• Metabolic risk profiling
• Identification of known pancreatitis risk factors

Key risk factors may include:

• History of gallstones
• High triglycerides
• Excess alcohol intake
• Prior episodes of unexplained abdominal pain
• Rapid metabolic changes or weight loss
• Concurrent medications affecting pancreatic or biliary function

This approach focuses on early identification of clinical risk patterns rather than late biochemical changes.

What symptoms are important to monitor?

Important symptoms to monitor include:

• Persistent upper abdominal pain (especially central)
• Pain that radiates to the back
• Nausea or vomiting that does not resolve
• Pain that worsens after eating
• Abdominal tenderness or bloating
• Sudden loss of appetite with gastrointestinal discomfort

If these symptoms are severe, persistent, or worsening, medical evaluation is necessary.

How to reduce pancreatitis risk while on GLP-1 therapy

For individuals using GLP-1 medications, risk reduction focuses on supporting overall pancreatic and metabolic health:

• Avoid or limit alcohol intake
• Maintain healthy triglyceride levels through diet, exercise and regular monitoring
• Follow appropriate dose escalation protocols for GLP-1 therapy
• Manage gallstone risk where relevant (especially during rapid weight loss)
• Maintain hydration and balanced nutrition during appetite suppression
• Report persistent gastrointestinal symptoms early rather than waiting for lab changes

These strategies help reduce the likelihood of pancreatic stress during treatment.

Where can I learn more?

If you want to better understand pancreatitis risk in the context of GLP-1 medications, it is useful to explore our referenced literature:

• https://www.ccjm.org/content/ccjom/92/8/483.full.pdf
• https://www.endocrinepractice.org/article/S1530-891X(25)00749-9/fulltext
• https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00716-2/fulltext

GLP-1 receptor agonists produce weight loss primarily through central appetite suppression and sustained reduction in caloric intake. While commonly described as having a broad range of “side effects,” most observed clinical changes are not due to direct pharmacologic toxicity. Instead, they represent predictable physiological adaptations to chronic negative energy balance.

As caloric intake decreases, the body transitions into an energy-conserving state. This affects skeletal muscle maintenance, micronutrient status, hydration balance, endocrine signaling, and cognitive energy availability. These changes occur gradually and are best understood through longitudinal biomarker trends rather than isolated laboratory abnormalities.

Clinical interpretation should therefore focus on distinguishing adaptive changes from emerging deficiency states, particularly in patients experiencing rapid or sustained weight loss.

Energy Restriction and Global Metabolic Adaptation

The primary mechanism of GLP-1 therapy is hypothalamic appetite suppression, resulting in sustained caloric deficit. This drives systemic metabolic adaptation, including preferential fat oxidation, reduced glycogen storage, and decreased anabolic signaling.

Biomarkers

• Body weight: Integrative marker of cumulative energy balance. Rapid declines may indicate excessive caloric restriction or inadequate nutritional compensation.
• Body composition: Differentiates fat mass reduction from lean mass loss. Disproportionate lean mass reduction suggests insufficient protein intake or excessive energy deficit.
• Albumin: Reflects long-term protein-energy status. It is a late and non-specific marker influenced by inflammation, hydration status, and hepatic function.

Fatigue and Reduced Energy Availability

Fatigue in GLP-1 therapy is most commonly a consequence of sustained caloric deficit rather than a direct pharmacologic effect. Reduced energy intake leads to lower glycogen reserves and reduced metabolic substrate availability, which can manifest as reduced stamina, slower recovery, and generalized low energy.

Biomarkers

• C-peptide: Reflects endogenous insulin secretion and overall beta-cell activity. In this context, it is used as a proxy for physiologic metabolic drive. Lower or declining values may be consistent with reduced nutrient stimulation and overall lower anabolic signaling during sustained caloric restriction.
• HbA1c: Reflects long-term glycemic exposure and overall metabolic stability. It does not capture acute fatigue but helps contextualize systemic metabolic control during weight loss.
• Albumin: May decline in prolonged energy restriction but is a late and non-specific marker of nutritional status.
• Body weight: Provides the most practical contextual indicator of energy deficit severity and duration.

Cognitive Effects and Energy Substrate Limitation

Cognitive symptoms such as reduced concentration, mental fatigue, or “brain fog” are generally linked to reduced systemic energy availability rather than direct central nervous system effects of GLP-1 signaling.

Biomarkers

• C-peptide: Reflects endogenous insulin production and overall metabolic signaling capacity. In this context, lower values may indicate reduced anabolic and energy-replete signaling states during sustained caloric restriction.
• HbA1c: Provides long-term glycemic context but does not reflect acute cognitive energy availability.

Lean Mass Loss and Protein-Energy Imbalance

Lean mass reduction occurs when protein intake is insufficient to match energy deficit. This is a clinically important concern during GLP-1–induced weight loss, particularly in cases of rapid or sustained reduction in body weight.

Biomarkers

• Body composition: Gold standard for assessing lean mass changes. A disproportionate decline in lean mass relative to fat mass indicates muscle catabolism.
• Total protein: Reflects circulating protein availability but lacks sensitivity for early muscle loss.
• Albumin: Late marker of protein-energy deficiency; non-specific and influenced by multiple physiological states.

Micronutrient Deficiency States

Reduced caloric intake and smaller meal volume can lead to progressive micronutrient depletion over months, particularly in iron, vitamin B12, and folate.

Biomarkers

• Ferritin: Primary indicator of iron stores. Declining levels precede anemia and reflect early depletion.
• Iron studies (serum iron, TIBC, transferrin saturation): Assess functional iron availability. Low transferrin saturation with low ferritin confirms iron deficiency.
• Vitamin B12: Essential for hematologic and neurologic function. Deficiency develops gradually and may precede clinical symptoms.
• Folate: Required for DNA synthesis and erythropoiesis. Low levels contribute to macrocytic anemia and fatigue.

Vitamin D Insufficiency

Vitamin D status may decline during GLP-1 therapy due to reduced dietary intake and altered adipose tissue distribution affecting storage dynamics.

Biomarkers

• 25-hydroxyvitamin D: Primary circulating form and most reliable marker of vitamin D status. Decline reflects reduced intake or altered bioavailability during weight loss.

Hydration Status and Renal Function Changes

Reduced appetite and gastrointestinal side effects frequently lead to decreased fluid intake, resulting in mild dehydration and hemoconcentration. These changes are typically functional and reversible.

Biomarkers

• Blood urea nitrogen (BUN): Increases in dehydration due to reduced renal clearance of urea.
• Creatinine: May rise secondary to hemoconcentration rather than true decline in glomerular filtration.
• BUN/creatinine ratio: Elevated ratio suggests relative dehydration rather than intrinsic renal pathology.
• Estimated glomerular filtration rate (eGFR): May decrease transiently in volume depletion but typically normalizes with rehydration.

Endocrine Adaptation and Sex Hormone Modulation

Weight loss alters endocrine signaling through reduced adipose tissue mass, affecting aromatase activity and sex hormone binding globulin production. These changes influence both total and bioavailable sex hormones.

Biomarkers

• Testosterone: Reflects total androgen production but does not distinguish free from bound hormone.
• SHBG: Typically increases with weight loss, reducing free hormone availability.
• Free testosterone: Best indicator of biologically active androgen status.
• Estradiol: May decline due to reduced peripheral aromatization in adipose tissue.

Cortisol and Stress Axis Activation

Caloric restriction may activate the hypothalamic-pituitary-adrenal axis as a physiological adaptation to perceived energy scarcity. This is typically mild and adaptive rather than pathological.

Biomarkers

• Morning cortisol: Reflects baseline adrenal activity. Mild elevation may represent physiological adaptation to energy restriction.

Gallbladder Physiology and Rapid Weight Loss

Rapid weight loss increases the risk of gallstone formation through bile supersaturation with cholesterol and reduced gallbladder contractility. This leads to bile stasis, which promotes crystallization and gallstone development. The process is typically gradual and asymptomatic until biliary obstruction or inflammation occurs.

Biomarkers

• ALP (alkaline phosphatase): Primary marker of cholestatic injury. Elevates in biliary obstruction due to impaired bile flow and is one of the earliest biochemical signals of gallbladder or bile duct involvement.
• ALT and AST: Hepatocellular enzymes that may rise secondarily if there is associated liver stress or inflammation, but they are not sensitive or specific for gallstone disease itself.
• Bilirubin: Reflects impaired bile excretion. Typically increases in more advanced obstruction when bile flow is significantly impaired, often alongside symptoms such as jaundice.

Hair Loss and Telogen Effluvium

Hair shedding associated with GLP-1 therapy is most consistent with telogen effluvium, a stress-related shift in hair follicle cycling triggered by rapid weight loss and nutrient depletion.

Biomarkers

• Ferritin: Strongly associated with hair follicle activity. Low levels correlate with increased shedding risk.
• Iron studies: Assess systemic iron availability relevant to follicular function.
• Vitamin B12: Supports cellular turnover in rapidly dividing tissues.
• Folate: Required for DNA synthesis in follicular growth.
• Albumin: Reflects overall protein-energy status.
• Vitamin D: May influence follicular cycling and local immune regulation.

Literature

• Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss
• Does GLP-1 Make You Tired? Causes and Fixes
• A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists
• The GLP-1 Aftermath: What the Science Says About Muscle Loss and Cellular Aging
• Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists
• Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes
• Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes
• GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and Humans
• Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
• Predictors and Characteristics of Hair Loss Among Users of GLP‐1 Receptor Agonists

A hematocrit test (Hct) measures how much of your blood consists of red blood cells. Capillary hematocrit refers specifically to the measurement obtained using a small capillary tube — a method also called the microhematocrit technique, which requires a smaller blood sample and less time for the testing procedure. The result is expressed as a percentage, representing how much of your total blood volume is made up of red blood cells.

Blood is made of red blood cells, white blood cells, platelets, and plasma (the fluid part). Having a healthy number of red blood cells is important because they carry oxygen throughout your body.

Why is hematocrit important?

Hematocrit is often used as an indicator of the oxygen-carrying capacity of blood. It can also be used as an indicator of the health of the bone marrow where red blood cells are produced.

Hematocrit levels that are too high or too low can indicate a blood disorder, dehydration, or other medical conditions. An abnormally low hematocrit may suggest anemia, a decrease in the total amount of red blood cells, while an abnormally high hematocrit is called polycythemia.

How can I better understand my hematocrit levels?

Higher than normal hematocrit may indicate polycythemia or erythrocytosis. Causes of a high hematocrit include dehydration, low availability of oxygen (such as from smoking, high altitude, or pulmonary fibrosis).

Lower than normal hematocrit may indicate anemia or nutritional deficiencies. A low hematocrit with a low mean corpuscular volume (MCV) and a high red cell distribution width (RDW) suggests a chronic iron-deficient anemia resulting in abnormal hemoglobin synthesis. Decreased hematocrit levels could also indicate life-threatening diseases such as leukemia. Further evaluation, including a complete blood count (CBC) and medical history assessment, may be necessary to determine the underlying cause.

How can I maintain optimal hematocrit levels?

Maintaining balanced hematocrit levels involves the following steps:

Dietary Changes: Iron-rich foods work better when paired with vitamin C sources. Your body absorbs less iron if you consume caffeine and calcium with meals. Heme iron sources such as red meat, liver, poultry, fish, and seafood provide the most usable form of iron. Non-heme iron sources like beans, lentils, spinach, tofu, and fortified cereals provide plant-based iron. Vitamin B12, found in animal and dairy products, is essential for red blood cell production. Those following a vegetarian or vegan diet may need to take vitamin B12 supplements. Consuming a source of Vitamin C, like citrus fruits, bell peppers, or strawberries, alongside non-heme iron foods such as spinach or beans can significantly improve iron uptake.

Lifestyle Changes: Stay hydrated by drinking 8–12 glasses of water per day, engage in moderate exercise like brisk walking or light cycling, and avoid smoking, as it can negatively impact circulation and overall blood health. Engaging in intense physical activity, particularly endurance exercise, can stimulate the body to produce more red blood cells over time, helping improve oxygen delivery to working muscles. Stress takes a toll on blood health, as the body releases hormones that affect how blood flows and delivers oxygen, so managing stress is important for maintaining healthy hematocrit levels.

Supplementation: Supplements containing iron or B vitamins should only be taken after a confirmed deficiency is diagnosed by a doctor, as iron supplements can cause side effects like constipation, and excessive intake without a deficiency can lead to iron overload. In some cases, your physician may also recommend folate (vitamin B9) to support red blood cell production.

Where can I learn more?

• PubMed – Hematocrit
• Cleveland Clinic – Hematocrit Test
• NCBI Bookshelf – Hemoglobin and Hematocrit

DISCLAIMER: IF YOU ARE CONCERNED WITH ANY OF YOUR RESULTS, PLEASE CONSULT WITH YOUR PHYSICIAN.